Allogenic expanded Natural Killer Cells therapy (Singapore General Hospital)

N/A

Report date: 2026/04/03 20:03:44

Base Information

Drug NameAllogenic expanded Natural Killer Cells therapy (Singapore General Hospital)

Drug Alias NameAlloNK1

ClassificationCell and gene therapy > Cell therapy > Donor > AllogeneicCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapyCell and gene therapy > Cell therapy > Source of cells > PMBC-derived

Mechanisms of ActionNatural killer cell replacements

TargetsUpdating

Therapy Area/IndicationsNeoplasm, ResidualNasopharyngeal Carcinoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritorySingapore

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesSingapore General Hospital

China Registration ClassN/A

Develop Information

Active CompaniesSingapore General Hospital

Inactive CompaniesN/A

Active IndicationsNeoplasm, ResidualNasopharyngeal Carcinoma

Inactive IndicationsN/A

Other Information

ATC CodeN/A